40
Participants
Start Date
August 31, 2009
Primary Completion Date
April 30, 2011
Study Completion Date
April 30, 2011
BIIB022
IV Q3W
Sorafenib
Standard dosing of Sorafenib
Resesarch Site, Denver
Resesarch Site, Ocoee
Resesarch Site, Indianapolis
Resesarch Site, Boston
Resesarch Site, New York
Resesarch Site, Norfolk
Resesarch Site, Singapore
Resesarch Site, Tainan City
Resesarch Site, Taipei
Resesarch Site, Taoyuan District
Resesarch Site, Edgbaston
Lead Sponsor
Biogen
INDUSTRY